Adalank (N-Acetyl Selank Amidate) vs Cerebrolysin
Updated July 21, 2026 · Reviewed by the PeptidesDB Editorial team
A data-driven comparison of Adalank (N-Acetyl Selank Amidate) and Cerebrolysin (also searched as Cerebrolysin vs Adalank (N-Acetyl Selank Amidate)) — effect profiles, evidence, side effects, and which suits weight loss, muscle, or healing goals.
Verdict
Adalank (N-Acetyl Selank Amidate) centers on neuro, while Cerebrolysin leans toward neuro. On indexed research, Cerebrolysin is ahead (Adalank (N-Acetyl Selank Amidate): 0 studies, Emerging; Cerebrolysin: 1, Human evidence). Choose by goal — and read the primary studies. This is research information, not medical advice.
Key takeaways
- •Adalank (N-Acetyl Selank Amidate) is strongest for neuro; Cerebrolysin for neuro.
- •Evidence: Adalank (N-Acetyl Selank Amidate) Emerging (0 studies) vs Cerebrolysin Human evidence (1).
- •Both are research-use compounds — not FDA-approved.
Effect profiles, overlaid
At a glance
N-Acetyl Selank Amidate | Enhanced Tuftsin Analog
Neuropeptide Preparation | Neurological Recovery
Adalank (N-Acetyl Selank Amidate) vs Cerebrolysin: side-by-side
| Metric | Adalank (N-Acetyl Selank Amidate) | Cerebrolysin |
|---|---|---|
| Class | Cognitive | Cognitive |
| Regulatory status | Research use only | Research use only |
| Evidence grade | Emerging | Human evidence |
| Studies indexed | 0 | 1 |
| Research level | Emerging | Well Studied |
| Strongest effect | Neuro & mood | Neuro & mood |
| Healing & recovery | 0.0 | 3.0▲ |
| Muscle & body comp | 0.0 | 0.0 |
| Metabolic & appetite | 0.0 | 0.0 |
| Neuro & mood | 4.0 | 5.0▲ |
| Sleep & circadian | 0.0 | 0.0 |
| Inflammation & immune | 0.0 | 2.0▲ |
| Skin & aesthetics | 0.0 | 0.0 |
▲ marks the higher community effect score (0–5 perceived-effect signal, not clinical efficacy).
Mechanism & pharmacokinetics
| Property | Adalank (N-Acetyl Selank Amidate) | Cerebrolysin |
|---|---|---|
| Mechanism | Anxiolytic heptapeptide (Tuftsin analog) | — |
| Route | Intranasal / subcutaneous (research use) | — |
Established pharmacology — curated for well-characterized compounds and AI-summarized otherwise. A blank (—) means no reliable single value is published (half-life figures for some peptides genuinely disagree across sources). Verify against primary sources such as FDA labels and ClinicalTrials.gov.
What is Adalank (N-Acetyl Selank Amidate)?
Adalank (N-Acetyl Selank Amidate) is a modified analog of the Russian heptapeptide Selank, designed for enhanced metabolic stability and investigated for anxiolytic and nootropic effects.
Full Adalank (N-Acetyl Selank Amidate) profile, mechanism & studies →What is Cerebrolysin?
Cerebrolysin is a porcine brain-derived peptide preparation studied for stroke recovery, dementia, and TBI, with proposed neurotrophic and neuroprotective effects on the central nervous system.
Full Cerebrolysin profile, mechanism & studies →Which is better for your goal?
| Goal | Better fit | Why |
|---|---|---|
| Healing | Cerebrolysin | 3.0/5 effect signal |
| Neuro | Cerebrolysin | 5.0/5 effect signal |
| Inflammation | Cerebrolysin | 2.0/5 effect signal |
Fit reflects community-perceived effect profiles — not head-to-head trials. Read each peptide's studies before deciding.
Can you stack Adalank (N-Acetyl Selank Amidate) and Cerebrolysin?
People sometimes combine peptides that target different pathways, but there is little controlled research on this specific pairing and the interactions aren't well characterized. Because neither compound is FDA-approved, we don't publish stacking or dosing protocols here. Any combination should be discussed with a qualified clinician.
Adalank (N-Acetyl Selank Amidate) vs Cerebrolysin: side effects
No community-reported effects logged yet.
No community-reported effects logged yet.
Anonymous community reports (count = number of reports), not clinical incidence rates.
What the research says
Adalank (N-Acetyl Selank Amidate) has 0 approved studies indexed (Emerging), and Cerebrolysin has 1 (Human evidence). The Librarian re-checks PubMed, Europe PMC and ClinicalTrials daily, so these counts move. Open each profile to read the summaries and sources.
Frequently asked questions
Is Adalank (N-Acetyl Selank Amidate) or Cerebrolysin better?
It depends on your goal. Adalank (N-Acetyl Selank Amidate) is strongest for neuro; Cerebrolysin for neuro. Cerebrolysin has more indexed studies (1). See the goal-by-goal breakdown above.
Which has more research, Adalank (N-Acetyl Selank Amidate) or Cerebrolysin?
Adalank (N-Acetyl Selank Amidate) has 0 approved studies indexed (Emerging); Cerebrolysin has 1 (Human evidence). Higher counts mean more to read, not proven superiority.
Can you stack Adalank (N-Acetyl Selank Amidate) and Cerebrolysin?
Some users combine peptides, but there's little controlled data on this specific pairing, and interactions aren't well characterized. We don't publish stacking protocols for compounds that aren't FDA-approved. Discuss any combination with a qualified clinician.
What are the side effects of Adalank (N-Acetyl Selank Amidate) vs Cerebrolysin?
Adalank (N-Acetyl Selank Amidate): no community-reported effects logged yet. Cerebrolysin: none logged yet. These are anonymous reports, not incidence rates — see each profile.
Is Adalank (N-Acetyl Selank Amidate) or Cerebrolysin FDA-approved?
Adalank (N-Acetyl Selank Amidate) is a research-use compound and is not FDA-approved. Cerebrolysin is not FDA-approved. Research-use status is not a legal clearance to compound or use in humans.
Is Cerebrolysin better than Adalank (N-Acetyl Selank Amidate)?
For neuro, Cerebrolysin has the edge; for neuro, Adalank (N-Acetyl Selank Amidate) does. Neither is universally "better" — it's goal-dependent, and both should be weighed against their evidence base above.
Comparing related peptides
Regulatory & legal status
Adalank (N-Acetyl Selank Amidate) and Cerebrolysin are research-use compounds and are not FDA-approved for human use. FDA approval and compounding rules for peptides change frequently, and research-use status is not a legal clearance for human use. The FDA does not review compounded drugs for safety, effectiveness, or quality. Verify current status with primary sources before acting. Last reviewed July 21, 2026.